

Haematologica
HAEMATOL/2015/137083
Version 4

Analysis of renal impairment in MM-003, a phase 3 study of pomalidomide + low dose dexamethasone vs high dose dexamethasone in refractory or relapsed and refractory multiple myeloma

Katja C. Weisel, Meletios A. Dimopoulos, Philippe Moreau, Martha Q. Lacy, Kevin W. Song, Michel Delforge, Lionel Karlin, Hartmut Goldschmidt, Anne Banos, Albert Oriol, Adrian Alegre, Christine Chen, Michele Cavo, Laurent Garderet, Valentina Ivanova, Joaquin Martinez-Lopez, Stefan Knop, Xin Yu, Kevin Hong, Lars Sternas, Christian Jacques, Mohamed H. Zaki, and Jesus San Miguel

Disclosures: KCW has consulted for and received honoraria and travel support from Amgen, Bristol-Myers Squibb, Celgene, Janssen, has received research funding from Celgene, Janssen, has consulted for and received honoraria from Onyx, has received travel support from Novartis and Takeda, and has consulted for Noxxon; MAD has received honoraria from Amgen, Celgene, Janssen, Onyx, Ortho Biotech, and Novartis; PM has received honoraria from and consulted for Celgene, Takeda, Janssen, BMS; MQL has received research funding from Celgene; KWS has participated in advisory boards, received honoraria, and research funding from Celgene and Janssen; MD has consulted for Celgene and Janssen-Cilag; LK has participated in expert board committees for Celgene and Sandoz and received honoraria from Celgene and Janssen; HG has participated in advisory boards, speakers bureau, and received honoraria research funding from Celgene; AO has participated in advisory boards and received honoraria from Celgene; AA has participated in advisory boards for Celgene and Janssen-Cilag and received research funding from Amgen, Celgene, and Jansen-Cilag; CC has consulted for, received research funding from, and honoraria from Celgene; MC has consulted for and received honoraria from Bristol-Myers Squibb, Celgene, Janssen, and Millennium; JML has received research funding from Celgene and Novartis and has received honoraria from Bristol-Myers Squibb, Celgene, Novartis, and Janssen; SK has participated in advisory boards, received honoraria from, and received research funding from Celgene; XY, KH, LS, CJ, and MHZ are employed by and have equity ownership with Celgene; JFSM has consulted for Bristol-Myers Squibb, Celgene, Merck, Millennium, Novartis, and Onyx; AB, LG, and VI have no conflict of interest disclosures.

Contributions: MAD, PM, AA, XY, KH, LS, CJ, MZ, JSM contributed to the conception of the work; MD, XY, KH, LS, CJ, MZ, JSM contributed to the design of the work; KW, MAD, PM, KS, MD, LK, HG, AB, AO, LG, MC, VI, AA, JML, CC, SK, XY, KH, LS, CJ, MZ, JSM contributed to the acquisition, analysis, or interpretation of data for the work. KW, MAD, PM, KS, MD, LK, HG, AB, AO, AA, CC, MC, LG, VI, JML, SK, XY, KH, LS, CJ, MZ, JSM contributed to revising the manuscript critically for important intellectual content and approved the final version of the manuscript.